% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Balss:125471,
      author       = {J. Balss$^*$ and C. Thiede and T. Bochtler$^*$ and J. G.
                      Okun and M. Saadati$^*$ and A. Benner$^*$ and S. Pusch$^*$
                      and G. Ehninger and M. Schaich and A. D. Ho$^*$ and A. von
                      Deimling$^*$ and A. Krämer$^*$ and C. Heilig$^*$},
      title        = {{P}retreatment d-2-hydroxyglutarate serum levels negatively
                      impact on outcome in {IDH}1-mutated acute myeloid leukemia.},
      journal      = {Leukemia},
      volume       = {30},
      number       = {4},
      issn         = {1476-5551},
      address      = {Basingstoke},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2017-01597},
      pages        = {782 - 788},
      year         = {2016},
      abstract     = {Mutations in isocitrate dehydrogenases (IDHs) 1 and 2
                      frequently occur in acute myeloid leukemia (AML) and result
                      in the production of the oncometabolite d-2-hydroxyglutarate
                      (D2HG). D2HG has been shown to promote leukemogenesis even
                      in the absence of mutated IDH, but the prognostic
                      significance of pretreatment serum D2HG levels in patients
                      with IDH-mutated AML is unclear. We measured D2HG serum
                      levels in 84 patients with IDH-mutated AML treated in the
                      prospective, randomized multicenter AML2003 trial of the
                      German Study Alliance Leukemia. Multivariate Cox regression
                      showed D2HG levels to negatively impact on event-free
                      survival (EFS) as a continuous variable in the entire
                      IDH(mut) cohort (P=0.04), with no effect on overall survival
                      (OS). In a subgroup analysis, the negative impact of D2HG on
                      EFS was found to be restricted to patients with mutations in
                      IDH1 (P=0.003), adjusted for age, leukocyte count, serum
                      lactate dehydrogenase and European LeukemiaNet risk score.
                      We thus conclude that pretreatment D2HG serum levels may
                      yield prognostic information in patients with IDH1-mutated,
                      but not in IDH2-mutated AML, possibly due to different
                      subcellular localizations of IDH1 and IDH2.},
      keywords     = {Biomarkers, Tumor (NLM Chemicals) / Glutarates (NLM
                      Chemicals) / alpha-hydroxyglutarate (NLM Chemicals) /
                      Isocitrate Dehydrogenase (NLM Chemicals) / IDH1 protein,
                      human (NLM Chemicals)},
      cin          = {G380 / G330 / C060 / L101 / L301},
      ddc          = {610},
      cid          = {I:(DE-He78)G380-20160331 / I:(DE-He78)G330-20160331 /
                      I:(DE-He78)C060-20160331 / I:(DE-He78)L101-20160331 /
                      I:(DE-He78)L301-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:26582645},
      doi          = {10.1038/leu.2015.317},
      url          = {https://inrepo02.dkfz.de/record/125471},
}